FDA Approvals - Novartis' biogeneric wins breakthrough approval from FDA (Pharmaceutical Business Review)
Novartis' biogeneric wins breakthrough approval from FDA (Pharmaceutical Business Review)
In a landmark decision the FDA has approved Novartis biogeneric drug Omnitrope for the treatment of growth disorders in children and adults.
Increased Survival and High Response Rates Reported for Introgen's ADVEXIN P53 Therapy (RedNova)
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Researchers at Introgen Therapeutics, Inc.